Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Biomerica, Inc. is a global biomedical company that develops, manufactures and mar...
Biomerica, Inc. is a global biomedical company ...
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...
Astellas Pharma Inc. is a pharmaceutical compan...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development a...
DelMar Pharmaceuticals is a biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.